摘要
低级别胶质瘤是常见的颅内肿瘤,虽然常被认为是良性肿瘤,但低级别胶质瘤患者临床预后差异极大,而且世界范围内对于低级别胶质瘤的治疗仍有较大争议。是否所有低级别胶质瘤都需要手术治疗?手术后是否需要辅以放疗?化疗是否必要?化疗能否替代放射治疗?还需要多中心大样本的前瞻性研究获得证据。而深入了解低级别胶质瘤的分子生物学特征,采用适当的技术显示其恶性进展的特征对治疗决策十分有用。
Low grade gliomas（LGGs） are common tumors in central nervous system. They usually be considered as benign, although their prognosis varied widely. There is no standerd treatment protocal for LGGs yet currently. Do all LGGs should receive surgery？ Do radiotherapy and/or chemotherapy essential following surgery？ And does chemotherapy can replace radiotherapy？ All these unsure points need to be clarified through large clinical trial. Nevertheless, understanding molecular charicteristics, and by using advanced technology to determine malignancy progression evidence are very important for treatment decision of LGGs.
出处
《中国神经肿瘤杂志》
2008年第2期75-78,共4页
Chinese Journal of Neuro-Oncology
关键词
低级别胶质瘤
治疗
Low grade glioma
Treatment
